about
Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involvedDifferential gene expression induced by insulin and insulin-like growth factor-II through the insulin receptor isoform AIntegrated insulin pump therapy with continuous glucose monitoring for improved adherence: technology updateThe IGF system in thyroid cancer: new concepts.Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease.Insulin analogs and cancer.Insulin and its analogs: actions via insulin and IGF receptors.IGF-II binding to insulin receptor isoform A induces a partially different gene expression profile from insulin binding.Biological effects of insulin and its analogs on cancer cells with different insulin family receptor expression.IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.Insulin receptor isoforms are differently expressed during human osteoblastogenesis.Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma.Role of c-Abl in directing metabolic versus mitogenic effects in insulin receptor signaling.Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1.Nuclear translocation of insulin receptor substrate-1 by the insulin receptor in mouse embryo fibroblasts.Functional insulin receptors are overexpressed in thyroid tumors: is this an early event in thyroid tumorigenesis?Insulin receptors in breast cancer.Type I insulin-like growth factor receptor function in breast cancer.Papillary thyroid microcarcinomas: a comparative study of the characteristics and risk factors at presentation in two cancer registries.In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A.Type 2 diabetic patients with Graves' disease have more frequent and severe Graves' orbitopathy.Long-acting insulin analogs and cancer.Efficacy of real-time continuous glucose monitoring on glycaemic control and glucose variability in type 1 diabetic patients treated with either insulin pumps or multiple insulin injection therapy: a randomized controlled crossover trial.Insulin Receptor Isoforms in CancerInsulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanismA novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancerThe role of insulin receptors and IGF-I receptors in cancer and other diseasesComment on: Yang et al. (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes;59:1254-1260Obesity and cancerUse of insulin detemir during pregnancyRe: Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal womenDiabetes and cancerAdipose Tissue, Obesity and Adiponectin: Role in Endocrine Cancer RiskUse of insulin detemir in pregnancy: a report on 10 Type 1 diabetic women
P50
Q24301995-09A54581-557C-4E21-8243-9A6AFDBB927EQ24311360-77FEBA8F-8D53-4C9B-ACF1-A14BF6D863BEQ26785492-AAF49FE3-5971-4266-9E08-7ADFB0AA6E6DQ28365951-BCAD1999-DEA2-4D35-A00B-8E629510B2EBQ35002762-489FAD6A-2004-4610-A294-E1F7486610DDQ35971416-9A80A62B-04CC-44E9-B3EC-10E650D682C1Q37781725-0E014A63-752B-47DC-9DDF-FEC9E8DFAA66Q38332029-752235B2-F885-40DA-B35E-B9EEAF68C223Q39010079-7840F187-AE4D-44A9-A24B-DEAF306D5E31Q39032666-8FAD233F-C523-446E-96BC-E808C743D53BQ39371097-01E849C4-6289-4C92-A1C0-606A1F9D3718Q39877535-5CC37BB6-AFA0-4B3F-B507-CB929E62369AQ40109546-84A62DCA-92C9-4DA6-A5FE-3D084EAAC796Q40291617-10A20598-FD11-4D02-8315-B2BD58C6F44CQ40647974-9B2BB931-C8EF-40F5-9AD7-7A4F1CE0C339Q40653911-539911EB-D742-4506-97A0-6548BC5C33BEQ40972289-ABBE08F8-2E18-468E-943D-37CD6BBFD607Q40999350-084E10E2-E047-4723-8EBC-21F641F5E4E3Q41727242-9993A211-D530-483F-8D54-9AC39FEA6695Q41970718-72C4FDAC-BB7B-40C5-8341-37EDA601DBB0Q44226596-09A0B216-847C-4E55-B696-EBCD5BBC0CC4Q45138634-56473C2D-6A26-4F5D-AD55-2AA2E9CB717FQ53176461-346B6E12-C253-4855-A896-6186EDCFEEF2Q53553958-E78696ED-1D0E-4795-ADB6-13130E78FCEBQ59798959-E9469A48-8242-4F66-9748-2CE4CEF74708Q77402826-9E907ECB-6FA2-43AB-A434-11B52B97331CQ77481492-4F85F2AE-ADF4-4759-B8AC-8C66CD6CAA2FQ81238512-93513DE3-E670-47D0-9B17-8EA4B5E3BF01Q82080488-4D11DF7E-1321-48DA-898F-E61DD38E81C0Q82204786-D97B553D-FC46-49B3-A67D-E62968A74A8CQ83375317-5CEC4332-1752-47B3-8826-2AA558935A37Q84106339-3DEDEA60-6504-44E3-B353-E20CC2E9D4E2Q84262739-524D67D3-8658-48B1-8F3C-722BD1027A11Q92854261-0ED3A5A1-6878-46FE-9076-E7A1C531DA66Q94946546-EAE62199-4753-4434-A014-970FF97F9F48
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Laura Sciacca
@ast
Laura Sciacca
@en
Laura Sciacca
@es
Laura Sciacca
@nl
type
label
Laura Sciacca
@ast
Laura Sciacca
@en
Laura Sciacca
@es
Laura Sciacca
@nl
prefLabel
Laura Sciacca
@ast
Laura Sciacca
@en
Laura Sciacca
@es
Laura Sciacca
@nl
P106
P1153
6601980351
P21
P31
P496
0000-0002-3258-7200